Kisspeptin-10 is a KISS1R agonist upstream of GnRH. Real Phase 2 reproductive-axis trials from the Dhillo/Seminara groups. The longevity-adjacency framing is speculative. Mechanism, half-life, what we don't know. RUO research reference.
For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound.
Disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full FTC disclosure on the About page.
Kisspeptin-10 is the 10-amino-acid C-terminal fragment of the kisspeptin protein — the active sequence the receptor actually sees. The full protein is encoded by the KISS1 gene and processed into shorter active fragments; the 10-mer (KP-10) is one of those fragments and the one that shows up in research peptide markets.
Category: hormonal and reproductive-axis research compound. Same conversation as hCG and the GnRH agonists on the HPG-axis side, and same conversation as the GH secretagogues on the broader endocrine-modulation side, but a different target than either.
The single-line summary: KISS1R agonist, upstream regulator of the hypothalamic-pituitary-gonadal axis. It sits one step earlier in the cascade than the molecules most operators are paying attention to.
The two foundational research programs to know are Stephanie Seminara at Massachusetts General / Harvard, and Waljit Dhillo at Imperial College London. Seminara's group published the original genetic work establishing that loss-of-function mutations in KISS1R (the kisspeptin receptor, also called GPR54) cause hypogonadotropic hypogonadism in humans — that is the paper that established kisspeptin as a non-optional input to the reproductive axis. Dhillo's group has run most of the human pharmacology of administered kisspeptin, including the Phase 2 trial work.
The pathway, in plain English: Kisspeptin-secreting neurons in the hypothalamus signal into GnRH (gonadotropin-releasing hormone) neurons. GnRH neurons release GnRH in pulses into the hypothalamic-pituitary portal circulation, where it reaches the anterior pituitary. The pituitary releases LH (luteinizing hormone) and FSH (follicle-stimulating hormone). LH drives testosterone production in the testes in men and ovarian steroidogenesis in women. FSH drives gametogenesis. Kisspeptin is the upstream switch that determines whether the GnRH pulse generator runs.
One technical term worth unpacking: KISS1R is a G-protein-coupled receptor (formerly GPR54). When kisspeptin binds, the receptor activates Gq signaling in GnRH neurons, which depolarizes them and produces a GnRH pulse. The molecule is acting on the upstream pulse-generator, not on the testes or ovaries directly.
This is why kisspeptin is interesting in a research context where someone wants to probe the integrity of the HPG axis without bypassing it the way exogenous testosterone does. It is also why it is not a substitute for the molecules downstream of it — they answer different questions.
Half-life. Short. Plasma half-life of kisspeptin-10 is reported in the minutes range — under 5 minutes in some pharmacokinetic work — with hormonal effects (LH rise, downstream testosterone) measurable for hours after administration. The mismatch between plasma half-life and effect duration is itself a feature of the receptor pharmacology and is part of the dosing-pattern conversation.
Route. Intravenous and subcutaneous routes appear in research contexts. Intranasal preparations exist in community circles but the published support is thin. The Phase 2 trial work has predominantly used SC and IV administration.
The Compound's Tier framework: Tier 1 is large human RCTs. Tier 2 is smaller human studies or strong animal work in disease-relevant models. Tier 3 is mechanistic and preclinical. Tier 4 is hypothesis and N=1.
For kisspeptin-10, the tiering splits cleanly by what claim you are evaluating.
The community signal on kisspeptin-10 is dominated by N=1 self-experimentation around the HPG axis, and most of the chatter sits in a complicated pickle.
Acute libido reports. The most consistently reported subjective effect is acute change in sexual response within hours of administration. The published Tier 2 work is congruent with this; the community noise is louder than the trial signal but pointed in the same direction.
LH and testosterone monitoring. Operators who have run kisspeptin with serial labs report LH rises that are clean and reproducible at certain administration patterns and absent at others — the pulsatility-versus-continuous question is one community users discover empirically.
TRT-stack debate. Use among men already on exogenous testosterone is the contested ground. One community position is that kisspeptin downstream of TRT-suppressed LH is functionally muted and therefore not worth the vial. The opposing position is that it preserves an upstream signal worth preserving even in the suppressed state. The literature does not resolve this.
HCG comparison. The community framing that kisspeptin "does what hCG does" is mechanistically wrong — hCG is an LH-receptor agonist acting at the testes, while kisspeptin is upstream of LH itself. Operators who reason about the cascade, not just the hormonal outcome, do not conflate them.
Tachyphylaxis chatter. Whether sustained kisspeptin administration desensitizes the receptor over time is debated in both the literature and the community. The pulsatility argument — that the molecule's natural physiology is pulsed and that continuous exposure mismatches that — is the most-cited concern.
A short list.
The Compound covers kisspeptin-10 in the HPG-axis arc of the briefing, alongside hCG, GnRH-axis modulators, and the broader endocrine-modulation conversation that wraps around the GH secretagogue class. It is one of the molecules where the gap between "Tier 1 narrow trial corpus" and "Tier 4 vendor framing" is the widest in the stack — which is exactly the gap a curated weekly briefing exists to manage.
Related issues: Issue 1 — the HPG-axis primer.
Related compounds: CJC-1295 / Ipamorelin, MK-677, semaglutide (only because the GLP-1 class shows up next to kisspeptin in many founder protocols, not because the mechanism overlaps), hCG.
The full map covers 14 compounds, including kisspeptin-10, with the same mechanism-through-literature structure on each. If you read six newsletters on Sunday to assemble the picture, the Stack Map is the picture — assembled. Mechanism, half-life, primary literature pointers, what the community reports, what the literature still doesn't show.
Get the map: thecompoundbrief.com/peptide-stack-map
The Sunday briefing on peptides for founder-operators. One email. What's new in the literature, what survived peer review, what moved up or down on the operator stack, and the cited summaries that fit better behind the email gate than on a public page like this one.
Subscribe at thecompoundbrief.com.
For research use only. This page is a literature reference for research purposes. Nothing on it is medical advice, and nothing on it is a recommendation to administer, prescribe, or self-administer any compound discussed.
FDA disclaimer. None of the statements on this page have been evaluated by the U.S. Food and Drug Administration. Kisspeptin-10 is not approved for general human use in the United States. Research compounds are not intended for human consumption.
FTC disclosure. The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Editorial coverage on this site is independent of vendor selection. Full disclosure on the About page.
No medical advice. Consult a qualified medical professional before making any decisions about your health, medications, or supplementation.
14 compounds, half-lives, and the literature — one PDF.
Download the PDF →